Effect of Kunxian capsule, a novel Tripterygium wilfordii preparation, on reducing proteinuria and slowing renal function decline in diabetic kidney disease: a 48–week randomized controlled trial

医学 蛋白尿 厄贝沙坦 肾功能 雷公藤 泌尿科 不利影响 随机对照试验 内科学 肾脏疾病 入射(几何) 临床终点 糖尿病 胃肠病学 肾 局灶节段性肾小球硬化 急性肾损伤 肾小球硬化 临床试验 糖尿病肾病 外科 蛋白尿 内分泌学
作者
Shengnan Chen,Yajuan Gao,Zishen Liang,Yixue Zhang,Cui Wang,Yali Tang,Jun Zhao,Ani Wang,Yan Shen
出处
期刊:Renal Failure [Taylor & Francis]
卷期号:48 (1): 2755136-2755136
标识
DOI:10.1080/0886022x.2026.2755136
摘要

Background Diabetic kidney disease (DKD), a leading cause of chronic kidney disease, remains a clinical challenge despite renin–angiotensin system blockade. This study evaluated the efficacy and safety of adding Kunxian capsule to standard therapy with irbesartan in patients with DKD.Methods Eighty patients with DKD were randomly assigned to either the experimental group (standard therapy with irbesartan plus Kunxian capsule) or the control group (standard therapy with irbesartan) for 48 weeks. Primary outcomes included the proteinuria remission rate, degree of proteinuria reduction, and median time to remission. Secondary outcomes included the slope of eGFR decline and the incidence of renal composite hard endpoint. Safety was assessed by monitoring adverse events. This trial was registered in ClinicalTrials.gov on March 2, 2021 (No. NCT04981613).Results In the intention–to–treat analysis, the experimental group had a higher proteinuria remission rate (57.50% vs. 25.00%), a shorter median time to remission (5 months vs. not reached), and a greater reduction in 24–hour urinary protein than the control group. A lower incidence of renal composite hard endpoint was observed in the experimental group (10.00% vs. 32.50%), accompanied by a slower eGFR decline. No significant differences in the incidence of adverse events were observed between the two groups. Inflammatory markers, including C–reactive protein and erythrocyte sedimentation rate, were significantly reduced in the experimental group.Conclusions Adding Kunxian capsule to standard therapy with irbesartan improved the proteinuria remission rate and attenuated renal function decline in patients with DKD, supporting its potential as a promising adjunctive therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
俏皮绝山完成签到 ,获得积分10
刚刚
1秒前
xixi关注了科研通微信公众号
1秒前
APLYSIA完成签到,获得积分20
1秒前
wingmay完成签到,获得积分10
1秒前
1秒前
月落星沉发布了新的文献求助10
1秒前
ADJ发布了新的文献求助20
2秒前
2秒前
3秒前
BaooooooMao完成签到,获得积分0
4秒前
4秒前
4秒前
4秒前
5秒前
5秒前
汌舟完成签到,获得积分10
6秒前
6秒前
6秒前
吃点红糖馒头完成签到,获得积分10
6秒前
7秒前
7秒前
8秒前
橙尘尘发布了新的文献求助60
8秒前
张泽林发布了新的文献求助10
8秒前
8秒前
yu完成签到,获得积分10
9秒前
10秒前
10秒前
酷波er的应助被叶成会采纳,获得10
10秒前
10秒前
LLMs发布了新的文献求助10
10秒前
啦啦啦完成签到,获得积分10
11秒前
twistzz完成签到,获得积分10
11秒前
JamesPei的应助被zjs采纳,获得10
11秒前
宋宋发布了新的文献求助10
11秒前
Hello的应助被信wz采纳,获得10
12秒前
舒心飞珍发布了新的文献求助10
12秒前
stardust314的应助被林木有枝采纳,获得50
13秒前
崖林发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153442
求助须知:如何正确求助?哪些是违规求助? 9550127
关于积分的说明 21696715
捐赠科研通 7741908
什么是DOI,文献DOI怎么找? 3425483
关于科研通互助平台的介绍 2550608
邀请新用户注册赠送积分活动 2469152